Published in J Natl Cancer Inst on April 07, 2009
The influence of statin medications on prostate-specific antigen levels. J Natl Cancer Inst (2008) 2.46
Differential effects of candesartan and olmesartan on adipose tissue activity biomarkers in type II diabetic hypertensive patients. Hypertens Res (2010) 2.09
Hyperuricemia and cardiovascular disease risk. Expert Rev Cardiovasc Ther (2014) 2.07
Effect of telmisartan-amlodipine combination at different doses on urinary albumin excretion in hypertensive diabetic patients with microalbuminuria. Am J Hypertens (2007) 1.56
Different actions of losartan and ramipril on adipose tissue activity and vascular remodeling biomarkers in hypertensive patients. Hypertens Res (2010) 1.54
Effect of body weight loss and normalization on blood pressure in overweight non-obese patients with stage 1 hypertension. Hypertens Res (2010) 1.54
Fibrinolysis and insulin sensitivity in imidapril and candesartan (FISIC study) recipients with hypertension. Hypertens Res (2010) 1.40
Irbesartan and hydrochlorothiazide association in the treatment of hypertension. Curr Vasc Pharmacol (2009) 1.40
Prospects for the development of novel anti-hyperlipidemic drugs. Curr Opin Investig Drugs (2006) 1.27
Matrix metalloproteinase-2, -9, and tissue inhibitor of metalloproteinase-1 in patients with hypertension. Endothelium (2006) 1.27
Effect of valsartan addition to amlodipine on insulin sensitivity in overweight-obese hypertensive patients. Intern Med (2008) 1.19
Berberine on metabolic and cardiovascular risk factors: an analysis from preclinical evidences to clinical trials. Expert Opin Biol Ther (2012) 1.18
Effect of delapril/manidipine vs olmesartan/ hydrochlorothiazide combination on insulin sensitivity and fibrinogen in obese hypertensive patients. Intern Med (2008) 1.08
Comparison between metalloproteinases-2 and -9 in healthy subjects, diabetics, and subjects with acute coronary syndrome. Heart Vessels (2007) 1.05
Effects of sitagliptin or metformin added to pioglitazone monotherapy in poorly controlled type 2 diabetes mellitus patients. Metabolism (2009) 1.04
Changes in LDL fatty acid composition as a response to olive oil treatment are inversely related to lipid oxidative damage: The EUROLIVE study. J Am Coll Nutr (2008) 0.99
Antidiabetic therapy in real practice: indicators for adherence and treatment cost. Patient Prefer Adherence (2012) 0.96
Psychosocial factors and metabolic parameters: is there any association in elderly people? The Massa Lombarda Project. Aging Ment Health (2010) 0.96
Effects of amlodipine fosinopril combination on microalbuminuria in hypertensive type 2 diabetic patients. Am J Hypertens (2002) 0.96
Blood pressure control and inflammatory markers in type 2 diabetic patients treated with pioglitazone or rosiglitazone and metformin. Hypertens Res (2007) 0.95
Red yeast rice improves lipid pattern, high-sensitivity C-reactive protein, and vascular remodeling parameters in moderately hypercholesterolemic Italian subjects. Nutr Res (2013) 0.93
Elevated circulating LDL phenol levels in men who consumed virgin rather than refined olive oil are associated with less oxidation of plasma LDL. J Nutr (2010) 0.92
Effects of a combination of sitagliptin plus metformin vs metformin monotherapy on glycemic control, β-cell function and insulin resistance in type 2 diabetic patients. Diabetes Res Clin Pract (2012) 0.92
Hypertension: management perspectives. Expert Opin Pharmacother (2012) 0.91
A prospective evaluation of persistence on antihypertensive treatment with different antihypertensive drugs in clinical practice. Vasc Health Risk Manag (2007) 0.90
The effect of L-carnitine on plasma lipoprotein(a) levels in hypercholesterolemic patients with type 2 diabetes mellitus. Clin Ther (2003) 0.90
Effect of valsartan and ramipril on atrial fibrillation recurrence and P-wave dispersion in hypertensive patients with recurrent symptomatic lone atrial fibrillation. Am J Hypertens (2008) 0.90
Effects of n-3 PUFAs on postprandial variation of metalloproteinases, and inflammatory and insulin resistance parameters in dyslipidemic patients: evaluation with euglycemic clamp and oral fat load. J Clin Lipidol (2012) 0.89
Influence of metabolic syndrome superposition on familial combined hyperlipoproteinemia cardiovascular complication rate. Arch Med Sci (2013) 0.89
A comparison of the effects of pioglitazone and rosiglitazone combined with glimepiride on prothrombotic state in type 2 diabetic patients with the metabolic syndrome. Diabetes Res Clin Pract (2004) 0.89
Clinical perspectives of anti-inflammatory therapy in the elderly: the lipoxigenase (LOX)/cycloxigenase (COX) inhibition concept. Arch Gerontol Geriatr (2004) 0.89
Effect of telmisartan and ramipril on atrial fibrillation recurrence and severity in hypertensive patients with metabolic syndrome and recurrent symptomatic paroxysmal and persistent atrial fibrillation. J Cardiovasc Pharmacol Ther (2011) 0.89
Vascular remodeling and prothrombotic markers in subjects affected by familial combined hyperlipidemia and/or metabolic syndrome in primary prevention for cardiovascular disease. Endothelium (2007) 0.88
Evaluation of metalloproteinase 2 and 9 levels and their inhibitors in combined dyslipidemia. Clin Invest Med (2009) 0.88
Oral fat load effects on inflammation and endothelial stress markers in healthy subjects. Heart Vessels (2009) 0.88
Effects of losartan and amlodipine alone or combined with simvastatin in hypertensive patients with nonalcoholic hepatic steatosis. Eur J Gastroenterol Hepatol (2012) 0.88
Cardiometabolic Risks and Obesity in the Young. N Engl J Med (2016) 0.88
Cerebrovascular disease in Italy and Europe: it is necessary to prevent a 'pandemia'. J Cardiovasc Risk (2002) 0.87
Effect of antihypertensive treatment with valsartan or atenolol on sexual activity and plasma testosterone in hypertensive men. Eur J Clin Pharmacol (2002) 0.87
Comparison of the effects of valsartan and felodipine on plasma leptin and insulin sensitivity in hypertensive obese patients. Hypertens Res (2005) 0.87
Fenofibrate, simvastatin and their combination in the management of dyslipidaemia in type 2 diabetic patients. Curr Med Res Opin (2009) 0.87
Vildagliptin added to metformin on β-cell function after a euglycemic hyperinsulinemic and hyperglycemic clamp in type 2 diabetes patients. Diabetes Technol Ther (2012) 0.87
Variation of some inflammatory markers in hypertensive patients after 1 year of olmesartan/amlodipine single-pill combination compared with olmesartan or amlodipine monotherapies. J Am Soc Hypertens (2013) 0.86
Moderate consumption of olive oil by healthy European men reduces systolic blood pressure in non-Mediterranean participants. J Nutr (2007) 0.86
Effect of telmisartan on paroxysmal atrial fibrillation recurrence in hypertensive patients with normal or increased left atrial size. Clin Cardiol (2012) 0.86
Effects of amlodipine-atorvastatin combination on inflammation markers and insulin sensitivity in normocholesterolemic obese hypertensive patients. Eur J Clin Pharmacol (2006) 0.85
A randomized, double-blind, controlled, parallel-group comparison of perindopril and candesartan in hypertensive patients with type 2 diabetes mellitus. Clin Ther (2003) 0.85
Comparative evaluation of effect of valsartan/amlodipine and atenolol/amlodipine combinations on atrial fibrillation recurrence in hypertensive patients with type 2 diabetes mellitus. J Cardiovasc Pharmacol (2008) 0.85
Efficacy and tolerability of candesartan cilexetil/hydrochlorothiazide and amlodipine in patients with poorly controlled mild-to-moderate essential hypertension. J Renin Angiotensin Aldosterone Syst (2007) 0.84
Effect of telmisartan addition to amlodipine on ankle edema development in treating hypertensive patients. Expert Opin Pharmacother (2011) 0.84
Omega 3 polyunsaturated fatty acids supplementation and blood pressure levels in hypertriglyceridemic patients with untreated normal-high blood pressure and with or without metabolic syndrome: a retrospective study. Clin Exp Hypertens (2010) 0.84
Differential effects of lercanidipine and nifedipine GITS on plasma norepinephrine in chronic treatment of hypertension. Am J Hypertens (2003) 0.84
Metalloproteinase-2 and -9 in diabetic and nondiabetic subjects during acute coronary syndromes. Endothelium (2007) 0.84
Telmisartan and irbesartan therapy in type 2 diabetic patients treated with rosiglitazone: effects on insulin-resistance, leptin and tumor necrosis factor-alpha. Hypertens Res (2006) 0.83
Long-term effect of a dietary education program on postmenopausal cardiovascular risk and metabolic syndrome: the Brisighella Heart Study. J Womens Health (Larchmt) (2010) 0.83
Acarbose actions on insulin resistance and inflammatory parameters during an oral fat load. Eur J Pharmacol (2010) 0.83
Metalloproteinases in diabetics and nondiabetics during acute coronary syndromes and after 3 months. Endothelium (2007) 0.83
Orlistat and L-carnitine compared to orlistat alone on insulin resistance in obese diabetic patients. Endocr J (2010) 0.83
Hypertension and diabetes incidence: confounding factors. Hypertens Res (2011) 0.82
Gender-specific haemodynamic and metabolic effects of a sequential training programme on overweight-obese hypertensives. Blood Press (2009) 0.82
Alkaloids in the nature: pharmacological applications in clinical practice of berberine and mate tea. Curr Top Med Chem (2014) 0.82
Effects of a standardized oral fat load on vascular remodelling markers in healthy subjects. Microvasc Res (2010) 0.82
Relationship between serum uric acid and electrocardiographic alterations in a large sample of general population: data from the Brisighella Heart Study. High Blood Press Cardiovasc Prev (2014) 0.82
Retracted Acarbose on insulin resistance after an oral fat load: a double-blind, placebo controlled study. J Diabetes Complications (2011) 0.82
Effect of aliskiren addition to amlodipine on ankle edema in hypertensive patients: a three-way crossover study. Expert Opin Pharmacother (2011) 0.81
Effects of valsartan or ramipril addition to amlodipine/hydrochlorothiazide combination on left ventricular mass in diabetic hypertensive patients with left ventricular hypertrophy. Expert Opin Pharmacother (2012) 0.81
Vildagliptin action on some adipocytokine levels in type 2 diabetic patients: a 12-month, placebo-controlled study. Expert Opin Pharmacother (2012) 0.81
Modification of vascular and inflammation biomarkers after OGTT in overweight healthy and diabetic subjects. Microvasc Res (2010) 0.81
How to avoid the depression of the adherence to antihypertensive treatment? J Hypertens (2013) 0.81
Effects of nateglinide and glibenclamide on prothrombotic factors in naïve type 2 diabetic patients treated with metformin: a 1-year, double-blind, randomized clinical trial. Intern Med (2007) 0.81
Results from a 12 months, randomized, clinical trial comparing an olmesartan/amlodipine single pill combination to olmesartan and amlodipine monotherapies on blood pressure and inflammation. Eur J Pharm Sci (2013) 0.81
Effect of amlodipine-atorvastatin combination on fibrinolysis in hypertensive hypercholesterolemic patients with insulin resistance. Am J Hypertens (2004) 0.81
Effects of manidipine/delapril versus olmesartan/hydrochlorothiazide combination therapy in elderly hypertensive patients with type 2 diabetes mellitus. Hypertens Res (2008) 0.81
Olmesartan/amlodipine combination versus olmesartan or amlodipine monotherapies on blood pressure and insulin resistance in a sample of hypertensive patients. Clin Exp Hypertens (2012) 0.80
Combined lipoxygenase/cyclo-oxygenase inhibition in the elderly: the example of licofelone. Drugs Aging (2005) 0.80
Comparison of orlistat treatment and placebo in obese type 2 diabetic patients. Expert Opin Pharmacother (2010) 0.80
Retracted Evaluation of the positive effects on insulin-resistance and β-cell measurements of vildagliptin in addition to metformin in type 2 diabetic patients. Pharmacol Res (2013) 0.80
Metabolic effect of repaglinide or acarbose when added to a double oral antidiabetic treatment with sulphonylureas and metformin: a double-blind, cross-over, clinical trial. Curr Med Res Opin (2009) 0.80
Recommendations for the treatment of hypertension in patients with DM: critical evaluation based on clinical trials. Curr Clin Pharmacol (2006) 0.79
Sibutramine and L-carnitine compared to sibutramine alone on insulin resistance in diabetic patients. Intern Med (2010) 0.79
Different effect of psyllium and guar dietary supplementation on blood pressure control in hypertensive overweight patients: a six-month, randomized clinical trial. Clin Exp Hypertens (2007) 0.79
Candesartan effect on inflammation in hypertension. Hypertens Res (2010) 0.79
Activity of isoflavones and berberine on vasomotor symptoms and lipid profile in menopausal women. Gynecol Endocrinol (2012) 0.79
Effect of a sequential training programme on inflammatory, prothrombotic and vascular remodelling biomarkers in hypertensive overweight patients with or without metabolic syndrome. Eur J Cardiovasc Prev Rehabil (2009) 0.79
Efficacy and safety of two treatment combinations of hypertension in very elderly patients. Arch Gerontol Geriatr (2008) 0.79
Zofenopril and ramipril and acetylsalicylic acid in postmyocardial infarction patients with left ventricular systolic dysfunction: a retrospective analysis in hypertensive patients of the SMILE-4 study. J Hypertens (2013) 0.79
Comparison between orlistat plus l-carnitine and orlistat alone on inflammation parameters in obese diabetic patients. Fundam Clin Pharmacol (2010) 0.78
Effects of combination of sibutramine and L-carnitine compared with sibutramine monotherapy on inflammatory parameters in diabetic patients. Metabolism (2010) 0.78
Metabolic syndrome prevalence in Italy. Nutr Metab Cardiovasc Dis (2006) 0.78
Hepatic steatosis index and lipid accumulation product as middle-term predictors of incident metabolic syndrome in a large population sample: data from the Brisighella Heart Study. Intern Emerg Med (2012) 0.78